News
12-10-2009, 10:41 PM
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
More... (http://www.news-medical.net/news/20091211/Fulvestrant-500-mg-reduces-risk-of-disease-progression-in-women-with-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20091211/Fulvestrant-500-mg-reduces-risk-of-disease-progression-in-women-with-metastatic-breast-cancer.aspx)